Published in Drug Law Weekly, June 29th, 2004
Commenting on this announcement, Edmond Buccellato, CEO, stated: "Our patented treatment is directed at two of the main mediators of allergy and bronchial asthma, IgE and histamine. IgE is an immunoglobulin that plays a role in stimulating release of histamine. This release of histamine induces the allergic reaction that is the hallmark of the disease. It is one of the substances responsible for the symptoms of inflammation and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly